Xcout Intel
Attovia Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Subscribe to see Attovia Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Attovia Therapeutics, Inc. at a glance
Attovia Therapeutics, Inc. is a biotech company headquartered in San Carlos, United States. It is publicly listed (ATTO) with a market capitalisation of $697.5M. Xcout tracks 20 named people at Attovia Therapeutics, Inc., including Tao Fu (CEO, President & Director). Xcout recorded 11 job postings from Attovia Therapeutics, Inc. in the last 90 days.
Attovia Therapeutics, Inc. leadership
- Tao FuCEO, President & Director
- Steven ChanChief Financial Officer
- Hangjun ZhanChief Technology Officer
- Hubert C. ChenChief Medical Officer
- Petter VeibyChief Scientific Officer
- Hubert ChenChief Medical Officer
14 more named people on record for Attovia Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Hiring at Attovia Therapeutics, Inc.
Xcout recorded 11 job postings from Attovia Therapeutics, Inc. in the last 90 days, from a hiring record Xcout has kept since July 2026.
The weekly hiring trend, the roles and locations behind it — see Attovia Therapeutics, Inc.'s hiring signals →
Recent Attovia Therapeutics, Inc. news
- IPODas von Goldman Sachs unterstützte Unternehmen Attovia strebt bei seinem aufgestockten Börsengang in den USA eine Bewertung von 731,5 Millionen US-Dollar an
- IPODas von Goldman Sachs unterstützte Unternehmen Attovia strebt bei seinem aufgestockten Börsengang in den USA eine Bewertung von 731,5 Millionen US-Dollar an - TradingView
- IPOIPO registration (S-1)
- IPOAttovia files for IPO to take on Sanofi and Regeneron's ...
7 corporate events on record, with sources — see the full timeline →
Tech stack
Attovia Therapeutics, Inc. competitors
A few of Attovia Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
RAPT Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2015, the public company leverages its proprietary drug discovery platform to develop treatments for inflammatory and immunologic diseases.
AbbraTech Holdings LLC operates a platform technology focused on recombinant antibody discovery, engineering, and validation. The company targets human diseases such as cancer, immune disorders, and viral infections by developing antibodies for difficult-to-reach drug targets through its proprietary Epivolve technology.
Neomorph is a clinical-stage biotechnology company founded in 2020 and headquartered in San Diego, California. The company pioneers the discovery and development of molecular glue degraders to target and destroy difficult disease-causing proteins.
Valerio Therapeutics is a biotechnology company that develops precision-guided therapeutics for complex and underserved diseases. It utilizes a proprietary V-Body conjugate platform, based on synthetic single-domain antibody libraries, to enable targeted drug delivery and deep tissue penetration.
Atavistik Bio is a U.S. biotechnology company developing small-molecule medicines by targeting allosteric sites and metabolite-regulated biology, using its chemoproteomics and drug-discovery platform. Its programs are aimed at treating cancer and other serious diseases.
Ditto Biosciences is a company headquartered in San Francisco, US, that focuses on drug discovery. The company is involved in identifying proteins that could lead to new drugs for patients with autoimmune diseases.
Get Attovia Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Attovia Therapeutics, Inc. in Xcout Intel
- 20 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- 7 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access